Crescent Biopharma (CBIO) Revenue (2013 - 2026)

Crescent Biopharma (CBIO) reported Revenue of $1.0 million for Q1 2026, up 1285.33% quarter-over-quarter from $75000.0 in Q2 2022.

Crescent Biopharma (CBIO) Revenue (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has 8 years of Revenue data on file, last reported at $1.0 million in Q1 2026.

Revenue for Q1 2026 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (changed N/A YoY), and the FY2025 annual result was $10.8 million, changed N/A from the prior year.
Revenue climbed to $1.0 million in Q1 2026 per CBIO's latest filing, from $75000.0 in the prior quarter.
Over five years, Revenue peaked at $1.0 million in Q1 2026 and troughed at $75000.0 in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	5.21 Mn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	306.30 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.99 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Crescent Biopharma	486.92 Mn	297.76 Mn	-	1.04 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2026	1.04 Mn
Jun 30, 2022	75,000.00
Dec 31, 2021	17,625.00
Sep 30, 2021	86,560.00
Jun 30, 2021	142.00
Mar 31, 2021	1.06 Mn
Dec 31, 2020	162,935.00
Sep 30, 2020	1.00 Mn
Mar 31, 2020	9.00 Mn
Sep 30, 2016	18,500.00
Dec 31, 2015	35,375.00
Sep 30, 2015	35,375.00
Jun 30, 2015	20.00 Mn
Jun 30, 2014	15.03 Mn
Dec 31, 2013	77,413.00
Sep 30, 2013	52,571.00
Jun 30, 2013	55,074.00
Mar 31, 2013	3.81 Mn